NY Medical Midtown, Igor Kletsman MD

NY Medical Midtown operates under the direction of Igor Kletsman, MD, a physician holding dual board certifications in Family Medicine and Integrative Medicine, delivering peptide-based therapies and metabolic interventions to patients throughout New York, NY. Dr. Kletsman's dual certification framework allows the practice to address acute primary care needs while simultaneously implementing advanced protocols for weight management and hormonal balance, a combination that distinguishes this Midtown clinic from conventional family medicine offices. The practice maintains in-person consultation availability, enabling Dr. Kletsman and his clinical team to conduct comprehensive physical assessments, order onsite laboratory work, and adjust treatment protocols based on real-time patient response rather than relying solely on remote monitoring.

The clinic's peptide and metabolic therapy menu centers on three primary agents: NAD+ infusions for cellular energy restoration and neuroprotection, Semaglutide for GLP-1 receptor agonism in weight reduction programs, and Tirzepatide, a dual GIP/GLP-1 receptor agonist offering enhanced glycemic control and appetite regulation. Semaglutide protocols at NY Medical Midtown typically begin with subcutaneous dosing at 0.25 mg weekly, titrating upward based on tolerance and weight loss velocity, while Tirzepatide programs start at 2.5 mg weekly with similar escalation pathways. NAD+ administration occurs via intravenous infusion, with treatment frequencies ranging from weekly to monthly depending on whether the patient seeks cognitive support, metabolic enhancement, or recovery from chronic fatigue states. Dr. Kletsman's integrative medicine certification informs his approach to combining these peptides with nutritional counseling, micronutrient optimization, and lifestyle modification strategies rather than prescribing pharmacotherapy in isolation.

Dr. Kletsman's clinical philosophy integrates his family medicine foundation with functional and integrative principles, meaning patients receive continuity of care that spans from annual physicals and acute illness management to specialized peptide protocols and hormone replacement. His board certification in Integrative Medicine reflects formal training in evidence-based complementary modalities, nutrient therapeutics, and mind-body medicine, which he applies when designing individualized treatment plans for metabolic dysfunction, andropause, perimenopause, and age-related decline. The nursing staff at NY Medical Midtown handles phlebotomy, vital sign monitoring, and patient education regarding injection technique for at-home peptide administration, while the front desk coordinates insurance verification, prior authorizations for GLP-1 medications, and follow-up laboratory scheduling to track biomarkers such as hemoglobin A1c, lipid panels, and hormone levels throughout treatment.

Patients presenting for weight loss consultations at NY Medical Midtown undergo initial assessments that include body composition analysis, metabolic rate evaluation, and screening for underlying endocrine disorders such as hypothyroidism or insulin resistance before Dr. Kletsman recommends Semaglutide or Tirzepatide. Hormone optimization programs begin with comprehensive panels measuring total and free testosterone, estradiol, progesterone, DHEA-S, and thyroid function, followed by bioidentical hormone replacement or peptide adjuncts depending on deficiency patterns and patient goals. The practice's preventive care framework incorporates cardiovascular risk stratification, cancer screening adherence, and metabolic syndrome reversal strategies, positioning peptide therapy as one component within a broader health optimization model rather than a standalone intervention. Follow-up visits occur at intervals determined by treatment type—GLP-1 agonist patients typically return every four weeks during dose titration, while NAD+ recipients may schedule monthly or quarterly based on symptom resolution and energy restoration.

NY Medical Midtown's Midtown Manhattan location provides access to patients across the five boroughs and surrounding New York metropolitan area, with the in-person consultation model allowing Dr. Kletsman to perform physical examinations, assess injection site reactions, and modify protocols based on clinical findings that telehealth platforms cannot capture. The practice accepts various insurance plans for primary care services and conducts eligibility verification for Semaglutide and Tirzepatide coverage, though patients should anticipate out-of-pocket costs for peptides not covered by their specific plan formularies. The onsite laboratory capability enables same-visit blood draws with results integrated directly into treatment planning, reducing the delays associated with external lab referrals and allowing Dr. Kletsman to initiate or adjust peptide dosing based on current metabolic and hormonal data rather than outdated values.